<DOC>
	<DOC>NCT01187303</DOC>
	<brief_summary>The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).</brief_summary>
	<brief_title>Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>relapsed nodular lymphocyte predominant hodgkin lymphoma age 18 75 review of diagnosis by experienced pathologist no major organ dysfunction classical hodgkin lymphoma CD20 antibody treatment within the last 6 months prior enrollment chronic or current infectious disease requirering systemic antibiotics other past or current malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>